Discontinuing glucagon‐like peptide‐1 receptor agonists and body habitus: A systematic review and meta‐analysis

Documenti analoghi

• Safety and efficacy of glucagon‐like peptide‐1 (GLP‐1) receptor agonists in patients with weight regain or insufficient weight loss after metabolic bariatric surgery: A systematic review and meta‐analysis
  di: Ali Esparham, et al.
  Pubblicazione: (2024)
• Gut peptides before and following Roux‐En‐Y gastric bypass: A systematic review and meta‐analysis
  di: Mylène Simoneau, et al.
  Pubblicazione: (2024)
• Characterizing body composition modifying effects of a glucagon‐like peptide 1 receptor‐based agonist: A meta‐analysis
  di: Ruoyang Jiao, et al.
  Pubblicazione: (2024)
• Orforglipron, a novel non‐peptide oral daily glucagon‐like peptide‐1 receptor agonist as an anti‐obesity medicine: A systematic review and meta‐analysis
  di: Deep Dutta, et al.
  Pubblicazione: (2024)
• Effect of glucagon‐like peptide 1 receptor agonists on systolic blood pressure in patients with obesity, with or without diabetes: A systematic review and network meta‐analysis
  di: Abraish Ali, et al.
  Pubblicazione: (2025)